Article

Moderate glaucoma best served by aggressive IOP-lowering efforts

London-The Early Manifest Glaucoma Trial (EMGT) provides a unique set of data for the natural history of moderate glaucoma and demonstrates that lowering IOP by 25% protects against progression of visual field loss, according to Roger A. Hitchings, MD.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
Related Content
US News & World Report releases list of best ophthalmology ambulatory surgical centers in the US
March 18th 2025

US News & World Report releases list of best ophthalmology ambulatory surgical centers in the US

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

FDA approves expanded label for fluocinolone acetonide intravitreal implant
March 18th 2025

FDA approves expanded label for fluocinolone acetonide intravitreal implant

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Innovent Biologics announces approval of SYCUME in China for thyroid eye disease
March 18th 2025

Innovent Biologics announces approval of SYCUME in China for thyroid eye disease

Harrow launches partnership with mail-order pharmacy, PhilRx to expand access to VEVYE
March 17th 2025

Harrow launches partnership with mail-order pharmacy, PhilRx to expand access to VEVYE

© 2025 MJH Life Sciences

All rights reserved.